Reply to A. J. Cmelak et al and B. Kalra et al.

Autor: Chundury A; Anupama Chundury, MD, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ; Pippa F. Cosper, MD, Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI; and Sung Kim, MD, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ., Cosper PF; Anupama Chundury, MD, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ; Pippa F. Cosper, MD, Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI; and Sung Kim, MD, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ., Kim S; Anupama Chundury, MD, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ; Pippa F. Cosper, MD, Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI; and Sung Kim, MD, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ.
Jazyk: angličtina
Zdroj: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2021 Aug 20; Vol. 39 (24), pp. 2735-2736. Date of Electronic Publication: 2021 May 27.
DOI: 10.1200/JCO.21.00885
Abstrakt: Competing Interests: Sung KimConsulting or Advisory Role: NanobiotixNo other potential conflicts of interest were reported.
Databáze: MEDLINE